Expression of advanced glycation end products and their receptor in skin from patients with systemic sclerosis with and without calcinosis

Rheumatology

Volumn 48, Issue 8, 2009, Pages 876-882

  Davies, Christine A ^a   Herrick, Ariane L ^a   Cordingley, Lis ^a   Freemont, Anthony J ^a   Jeziorska, Maria ^a  

^a UNIVERSITY OF MANCHESTER   (United Kingdom)

Author keywords

Advanced glycation end products; Calcinosis; Immunohistochemistry; Skin; Systemic sclerosis

Indexed keywords

6 N CARBOXYMETHYLLYSINE; ADVANCED GLYCATION END PRODUCT; ADVANCED GLYCATION END PRODUCT RECEPTOR; CALCIUM CHANNEL BLOCKING AGENT; VASODILATOR AGENT; ADVANCED GLYCOSYLATION END PRODUCT RECEPTOR; ADVANCED GLYCOSYLATION END-PRODUCT RECEPTOR; IMMUNOGLOBULIN RECEPTOR;

ADULT; ANALYSIS OF VARIANCE; ARTICLE; CALCINOSIS; CONTROLLED STUDY; EXTRACELLULAR MATRIX; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; SCORING SYSTEM; SKIN BIOPSY; SKIN FIBROBLAST; SYSTEMIC SCLEROSIS; TISSUE DISTRIBUTION; VASCULAR ENDOTHELIUM; BIOPSY; CASE CONTROL STUDY; CHEMISTRY; COMPARATIVE STUDY; METABOLISM; MIDDLE AGED; NONPARAMETRIC TEST; PATHOLOGY; SKIN; TIME;

ADULT; ANALYSIS OF VARIANCE; BIOPSY; CALCINOSIS; CASE-CONTROL STUDIES; FEMALE; GLYCOSYLATION END PRODUCTS, ADVANCED; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; RECEPTORS, IMMUNOLOGIC; SCLERODERMA, SYSTEMIC; SKIN; STATISTICS, NONPARAMETRIC; TIME FACTORS;

EID: 70149099150     PISSN: 14620324     EISSN: 14620332     Source Type: Journal    
DOI: 10.1093/rheumatology/kep151     Document Type: Article

References (54)

1. Flavahan NA, Flavahan S, Mitra S, Chotani MA. The vasculopathy of Raynaud's phenomenon and scleroderma. Rheum Dis Clin North Am 2003;29:275-91.
2. Bruckdorfer KR, Hillary JB, Bunce T, Vancheeswaran R, Black CM. Increased susceptibility to oxidation of low-density lipoproteins isolated from patients with systemic sclerosis. Arthritis Rheum 1995;38:1060-7.
3. Stein CM, Tanner SB, Awad JA, Roberts LJ, Morrow JD. Evidence of free radicalmediated injury (isoprostane overproduction) in scleroderma. Arthritis Rheum 1996;39:1146-50.
4. Simonini G, Cerinic MM, Generini S et al. Oxidative stress in systemic sclerosis. Mol Cell Biochem 1999;196:85-91.
5. Herrick AL, Illingworth KJ, Hollis S, Gomez-Zumaquero JM, Tinahones FJ. Antibodies against oxidized low-density lipoproteins in systemic sclerosis. Rheumatology 2001;40:401-5.
6. Cotton SA, Herrick AL, Jayson MI, Freemont AJ. Endothelial expression of nitric oxide synthases and nitrotyrosine in systemic sclerosis skin. J Pathol 1999;189:273-8.
7. Sambo P, Baroni SS, Luchetti M et al. Oxidative stress in scleroderma: maintenance of scleroderma fibroblast phenotype by the constitutive up-regulation of reactive oxygen species generation through the NADPH oxidase complex pathway. Arthritis Rheum 2001;44:2653-64.
8. Yan SD, Schmidt AM, Anderson GM et al. Enhanced cellular oxidant stress by the interaction of advanced glycation end products with their receptors/binding proteins. J Biol Chem 1994;269:9889-97.
9. Fu MX, Requena JR, Jenkins AJ, Lyons TJ, Baynes JW, Thorpe SR. The advanced glycation end product, Nepsilon-(carboxymethyl)lysine, is a product of both lipid peroxidation and glycoxidation reactions. J Biol Chem 1996;271:9982-6.
10. Wautier J-L, Schmidt AM. Protein glycation: a firm link to endothelial cell dysfunction. Circ Res 2004;95:233-8.
11. Bierhaus A, Humpert PM, Morcos M, Wendt T, Chavakis T, Arnold B et al. Understanding RAGE, the receptor for advanced glycation end products. J Mol Med 2005;83:876-86 [review].
12. Huang JS, Guh JY, Chen HC, Hung WC, Lai YH, Chuang LY. Role of receptor for advanced glycation end-product (RAGE) and the JAK/STAT-signaling pathway in AGE-induced collagen production in NRK-49F cells. J Cell Biochem 2001;81: 102-13.
13. Yeh CH, Sturgis L, Haidacher J et al. Requirement for p38 and p44/ p42 mitogenactivated protein kinases in RAGE-mediated nuclear factor-kappaB transcriptional activation and cytokine secretion. Diabetes 2001;50:1495-504.
14. Yan SF, Ramasamy R, Naka Y, Schmidt AM. Glycation, inflammation, and RAGE: a scaffold for the macrovascular complications of diabetes and beyond. Circ Res 2003;93:1159-69.
15. Schleicher ED, Wagner E, Nerlich AG. Increased accumulation of the glycoxidation product N(epsilon)-(carboxymethyl)lysine in human tissues in diabetes and aging. J Clin Invest 1997;99:457-68.
16. Sakata N, Imanaga Y, Meng J et al. Immunohistochemical localization of different epitopes of advanced glycation end products in human atherosclerotic lesions. Atherosclerosis 1998;141:61-75.
17. Sasaki N, Toki S, Chowei H et al. Immunohistochemical distribution of the receptor for advanced glycation end products in neurons and astrocytes in Alzheimer's disease. Brain Res 2001;888:256-62.
18. Foell D, Kane D, Bresnihan B et al. Expression of the pro-inflammatory protein S100A12 (EN-RAGE) in rheumatoid and psoriatic arthritis. Rheumatology 2003;42:1383-9.
19. Nienhuis HL, de Leeuw K, Bijzet J et al. Skin autofluorescence is increased in systemic lupus erythematosus but is not reflected by elevated plasma levels of advanced glycation endproducts. Rheumatology 2008;47:1554-8.
20. Steen VD, Powell DL, Medsger TA. Clinical correlations and prognosis based on serum autoantibodies in patients with systemic sclerosis. Arthritis Rheum 1988;31:196-203.
21. Wigley FM, Wise RA, Miller R, Needleman BW, Spence RJ. Anticentromere antibody as a predictor of digital ischemic loss in patients with systemic sclerosis. Arthritis Rheum 1992;35:688-93.
22. Vayssairat M, Hidouche D, Abdoucheli-Baudot N, Gaitz JP. Clinical significance of subcutaneous calcinosis in patients with systemic sclerosis. Does diltiazem induce its regression? Ann Rheum Dis 1998;57:252-4.
23. LeRoy EC, Black C, Fleischmajer R et al. Scleroderma (systemic sclerosis): classification, subsets and pathogenesis. J Rheumatol 1988;15:202-5.
24. Clements P, Lachenbruch P, Siebold J et al. Inter and intraobserver variability of total skin thickness score (modified Rodnan TSS) in systemic sclerosis. J Rheumatol 1995;22:1281-5.
25. Kimura T, Takamatsu J, Ikeda K, Kondo A, Miyakawa T, Horiuchi S. Accumulation of advanced glycation end products of the Maillard reaction with age in human hippocampal neurons. Neurosci Lett 1996;208:53-6.
26. Lohwasser C, Neureiter D, Weigle B, Kirchner T, Schuppan D. The receptor for advanced glycation end products is highly expressed in the skin and upregulated by advanced glycation end products and tumor necrosis factor-alpha. J Invest Dermatol 2006;126:291-9.
27. Brett J, Schmidt AM, Yan SD et al. Survey of the distribution of a newly characterized receptor for advanced glycation end products in tissues. Am J Pathol 1993; 143:1699-712.
28. Allanore Y, Borderie D, Lemarechal H, Ekindjian OG, Kahan A. Acute and sustained effects of dihydropyridine-type calcium channel antagonists on oxidative stress in systemic sclerosis. Am J Med 2004;116:595-600.
29. ε-(carboxymethyl)lysine are increased in systemic sclerosis. Rheumatology 2007;46:412-16.
30. Drinda S, Franke S, Ruster M et al. Identification of the receptor for advanced glycation end products in synovial tissue of patients with rheumatoid arthritis. Rheumatol Int 2005;25:411-13.
31. Sunahori K, Yamamura M, Yamana J, Takasugi K, Kawashima M, Makino H. Increased expression of receptor for advanced glycation end products by synovial tissue macrophages in rheumatoid arthritis. Arthritis Rheum 2006;54: 97-104.
32. Steen VD. Autoantibodies in systemic sclerosis. Semin Arthritis Rheum 2005;35: 35-42.
33. Distler JH, Jungel A, Pileckyte M et al. Hypoxia-induced increase in the production of extracellular matrix proteins in systemic sclerosis. Arthritis Rheum 2007;56: 4203-15.
34. Denton CP, Abraham DJ. Transforming growth factor-[beta] and connective tissue growth factor: key cytokines in scleroderma pathogenesis. Curr Opin Rheum 2001;13:505-11.
35. Denton CP, Black CM, Abraham DJ. Mechanisms and consequences of fibrosis in systemic sclerosis. Nat Clin Prac Rheumatol 2006;2:134-44 [review].
36. Ihn H. Scleroderma, fibroblasts, signalling, and excessive extracellar matrix. Curr Rheumatol Rep 2005;7:156-62.
37. Holmes A, Abraham DJ, Chen Y et al. Constitutive connective tissue growth factor expression in scleroderma fibroblasts is dependent on SP1. J Biol Chem 2003;278:41728-33.
38. Verrechia F, Mauviel A. Transforming growth factor-β signaling through the Smad pathway: role in extracellular matrix gene expression and regulation. J Invest Dermatol 2002;118:211-15.
39. Gruschwitz M, Muller PM, Sepp N, Hofer E, Fontana A, Wick G. Transcription and expression of transforming growth factor type beta in the skin of progressive systemic sclerosis: a mediator of fibrosis? J Invest Dermatol 1990;94:197-203.
40. Sfikakis P, McCune PK, Tsokos M, Aroni K, Vayiopoulis G, Tsokos GC. Immunohistological demonstration of transforming growth factor-β isoforms in the skin of patients with systemic sclerosis. Clin Immunol Immunopathol 1993;69: 199-204.
41. Higley H, Persichitte K, Chu S, Waegell W, Vancheeswaran R, Black C. Immunocytochemical localization and serologic detection of transforming growth factor beta 1. Association with type I procollagen and inflammatory cell markers in diffuse and limited systemic sclerosis, morphea, and Raynaud's phenomenon. Arthritis Rheum 1994;37:278-88.
42. Jeziorska M. Transforming growth factor-betas and CD105 expression in calcification and bone formation in human atherosclerotic lesions. Z Kardiol 2001;90:23-6.
43. Edsall LC, English JC III, Patterson JW. Calciphylaxis and metastatic calcification associated with nephrogenic fibrosing nephropathy. J Cutan Pathol 2004;31:247-53.
44. Brownlee M. Advanced protein glycosylation in diabetes and aging. Ann Rev Med 1995;46:223-34.
45. Paul RG, Bailey AJ. The effect of advanced glycation end-product formation upon cell-matrix interactions. Int J Biochem Cell Biol 1999;31:653-60.
46. Basta G, Lazzerini G, Massaro M et al. Advanced glycation end products activate endothelium through signal-transduction receptor RAGE: a mechanism for amplification of inflammatory responses. Circulation 2002;105:816-22.
47. Okamoto T, Yamagishi S, Inagaki Y et al. Angiogenesis induced by advanced glycation end products and its prevention by cerivastatin. FASEB J 2002;16: 1928-30.
48. Davies CA, Jeziorska M, Freemont AJ, Herrick AL. Expression of osteonectin and matrix Gla protein in scleroderma patients with and without calcinosis. Rheumatology 2006;45:1349-55.
49. Macko RF, Gelber AC, Young BA et al. Increasing circulating concentrations of the counteradhesive proteins SPARC and thrombospondin-1 in systemic sclerosis (scleroderma). Relationship to endothelial and platelet and cell activation. J Rheumatol 2002;29:2565-70.
50. Jandeleit-Dahm K, Rumble J, Cox AJ et al. SPARC gene expression is increased in diabetes-related mesenteric vascular hypertrophy. Microvasc Ras 2000;59:61-71.
51. Allanore Y, Borderie D, Lemarechal H, Ekindjian OG, Kahan A. Nifedipine decreases sVCAM-1 concentrations and oxidative stress in systemic sclerosis but does not affect the concentrations of vascular endothelial growth factor or its soluble receptor 1. Arthritis Res Ther 2004;6:R309-14.
52. Allanore Y, Borderie D, Perianin A, Lemarechal H, Ekindjian OG, Kahan A. Nifedipine protects against overproduction of superoxide anion by monocytes from patients with systemic sclerosis. Arth Res Ther 2005;7:R93-100.
53. Park L, Raman KG, Lee KJ et al. Suppression of accelerated diabetic atherosclerosis by the soluble receptor for advanced glycation endproducts. Nat Med 1998;4: 1025-31.
54. Kislinger T, Tanji N, Wendt T et al. Receptor for advanced glycation end products mediates inflammation and enhanced expression of tissue factor in vasculature of diabetic apolipoprotein E-null mice. Arterio Thromb Vasc Biol 2001; 21:905-10.